Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

Bell Potter Healthcare Conference Presentation

Wednesday, November 15, 2023 1 min read
Key Takeaway: Radiopharm Theranostics has announced the initiation of a Phase 1/2a clinical study for BetaBart (RV-01) and has received IND approval from the US FDA. The company also shared positive clinical updates across four of its programs. This presentation at the Bell Potter Healthcare Conference highlights their advancements in therapeutic development.

Market Sentiment Analysis

POSITIVE FACTORS

  • Radiopharm Theranostics has initiated a Phase 1/2a clinical study.
  • The company received IND approval from the US FDA.
  • Positive clinical updates have been provided across four programs.

Full Press Release Details

• Announcements
• November 15, 2023
Loading Viewer…

More Announcements & Updates

• Announcements
• November 26, 2021
• Announcements
• July 31, 2023
• Announcements
• March 3, 2023
• Announcements
• December 9, 2022

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is the focus of Radiopharm's clinical study?

The clinical study focuses on BetaBart (RV-01) in a Phase 1/2a setting.

What approval did Radiopharm receive from the FDA?

Radiopharm received IND approval to initiate its Phase I therapeutic clinical study.

When was the Bell Potter Healthcare Conference presentation?

The presentation occurred on November 15, 2023.

What updates did Radiopharm provide at the conference?

Radiopharm provided positive clinical updates across four of its programs.

Tags: RADX Viatris Investor Conferences Healthcare BetaBart Phase 1/2a FDA IND approval clinical study
Last updated: Nov 15, 2023